



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

4th April 2012 - News release

NEUPRO APPROVED FOR PARKINSON'S DISEASE

The U.S. Food and Drug Administration (FDA) have approved the use of UCB's drug Neupro (rotigotine transdermal system) in the U.S.A. for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's Disease and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). The FDA has also approved UCB's new formulation of Neupro. Neupro will be available in U.S. retail pharmacies in July 2012. For more information go to the News release :

<http://www.ucb.presscentre.com/News/Neupro-approved-by-U-S-FDA-for-Parkinson-s-Disease-and-Restless-Legs-Syndrome-2d6.aspx>

In April 2008, Neupro was withdrawn from use in the U.S.A. because specific batches of Neupro had deviated from their specification. In June 2009, UCB proposed new refrigerated storage conditions to alleviate crystallization on the patches. UCB made progress in reformulation and remained committed to bringing Neupro to U.S. patients. Neupro is a dopamine agonist patch that provides continuous drug delivery. Rather than being in tablet form, Neupro uses a transdermal patch. For more information go to Neupro :

<http://www.rxlist.com/script/main/art.asp?articlekey=88589>

For the most recent clinical trial results of Neupro go to the Clinical trial results :

<http://www.viartis.net/parkinsons.disease/news/110221.htm>

<http://www.viartis.net/parkinsons.disease/news/120325.pdf>

mail@viartis.net

©2012 Viartis